This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (69) Citing Articles via Google Scholar Google Scholar Articles by van der Meer, P. Articles by Schoemaker, R. G. Search for Related Content PubMed PubMed Citation Articles by van der Meer, P. Articles by Schoemaker, R. G.

Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction

Peter van der Meer, MD^_*,,_*, Erik Lipsic, MD^_*,, Robert H. Henning, MD, PhD, Kristien Boddeus, BSc, Jolanda van der Velden, PhD, Adriaan A. Voors, MD, PhD^_*, Dirk J. van Veldhuisen, MD, PhD, FACC^_*, Wiek H. van Gilst, PhD^_*, and Regien G. Schoemaker, PhD

^_* Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands
Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, the Netherlands
Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, the Netherlands

View larger version (29K): [in a new window]   Figure 1 Effects of myocardial infarction (MI) and erythropoietin (EPO) treatment on hemodynamic parameters. dLVP = developed left ventricular pressure; LVEDP = left ventricular end-diastolic pressure; LVSP = left ventricular systolic pressure; +dP/dtmax = maximal rate of increase; –dP/dtmax = decrease of ventricular pressure. *p < 0.05 vs. MI; **p < 0.01 vs. MI; #p < 0.01 vs. sham.

View larger version (29K): [in a new window]   Figure 2 Plasma N-terminal atrial natiuretic peptide (N-terminal ANP) levels. EPO = erythropoietin. *p < 0.05 vs. myocardial infarction (MI); **p < 0.01 vs. MI; #p < 0.01 vs. sham.

View larger version (69K): [in a new window]   Figure 3 (A) Gomori-stained sections in the left ventricular viable wall of the five different groups, showing individual myocytes. (B) Bar graphs showing the actual measurements for the myocyte cross-sectional area in the different experimental groups. EPO = erythropoietin; MI = myocardial infarction. #p < 0.05 vs. sham.

View larger version (33K): [in a new window]   Figure 4 Effects of myocardial infarction (MI) and erythropoietin (EPO) treatment on beta-myosin heavy chain (MHC) protein expression as a percentage of total MHC expression. *p < 0.05 vs. MI; #p < 0.01 vs. sham.

View larger version (73K): [in a new window]   Figure 5 (A) Tissue sections stained with lectin in the viable free wall of the five different groups, showing individual capillaries. (B) Actual measurements for capillary density in number of capillaries per mm2. (C) Bar graphs representing the capillary-to-myocyte ratio in the different treatment groups. EPO = erythropoietin. *p < 0.05 vs. myocardial infarction (MI); **p < 0.01 vs. MI; #p < 0.01 vs. sham.